This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Semba, S. Articles by Yamakawa, M. Search for Related Content PubMed PubMed Citation Articles by Semba, S. Articles by Yamakawa, M.

The in Vitro and in Vivo Effects of 2-(4-Morpholinyl)-8-phenyl-chromone (LY294002), a Specific Inhibitor of Phosphatidylinositol 3'-Kinase, in Human Colon Cancer Cells¹

First Department of Pathology, Yamagata University School of Medicine, Yamagata 990-9585, Japan

Purpose: Phosphatidylinositol 3'-kinase (PI3K) and Akt/protein kinase B(PKB) allow for escape from apoptosis in various human cancer cells. We postulated that 2-(4-morpholinyl)-8-phenyl-chromone (LY294002), a PI3K inhibitor, should inactivate Akt/PKB, consequently inhibiting cell proliferation and inducing apoptosis in vitro and in vivo.

Experimental Design: Human colon cancer cell lines (DLD-1, LoVo, HCT15, and Colo205) and their mouse xenografts (DLD-1 and LoVo) were used in this study. The expression of phosphorylated Akt (Ser⁴⁷³) and apoptosis in cancer cells were determined by immunoblotting and immunohistochemistry. To evaluate the activity of caspase-3 in culturing cells, the caspase colorimetric assay was also performed.

Results: LY294002 demonstrated a remarkable growth-inhibitory and apoptosis-inducing effect in these colon cancer cell lines, with decreased expression of phosphorylated Akt (Ser⁴⁷³). However, there was a great discrepancy between the sensitivity for LY294002 and the level of expression of phosphorylated Akt. Although the LoVo and Colo205 cells exhibited high sensitivity to LY294002 with increased apoptosis, the DLD-1 and HCT15 cells did not show rapid induction of apoptosis. The caspase-3 activity was significantly high in the LoVo cells but not in the DLD-1 cells. In the experiments using mouse xenografts, we found that LY294002 administration in vivo also resulted in suppression of tumor growth and induction of apoptosis, especially in the LoVo tumors, and therefore showed remarkable effectiveness in the mouse peritonitis carcinomatosa model.

Conclusions: PI3K-Akt/PKB plays an important role in colon cancer development and progression by helping to promote cell growth and allowing cells to escape apoptosis. These results propose the usefulness of LY294002 as an antitumoral agent for patients with colorectal cancer.

This article has been cited by other articles:

				A. B. Bialkowska, Y. Du, H. Fu, and V. W. Yang Identification of novel small-molecule compounds that inhibit the proproliferative Kruppel-like factor 5 in colorectal cancer cells by high-throughput screening Mol. Cancer Ther., March 1, 2009; 8(3): 563 - 570. [Abstract] [Full Text] [PDF]

				S.-i. Yaguchi, Y. Fukui, I. Koshimizu, H. Yoshimi, T. Matsuno, H. Gouda, S. Hirono, K. Yamazaki, and T. Yamori Antitumor activity of ZSTK474, a new phosphatidylinositol 3-kinase inhibitor. J Natl Cancer Inst, April 19, 2006; 98(8): 545 - 556. [Abstract] [Full Text] [PDF]

				K. Yamaguchi, S.-H. Lee, J.-S. Kim, J. Wimalasena, S. Kitajima, and S. J. Baek Activating Transcription Factor 3 and Early Growth Response 1 Are the Novel Targets of LY294002 in a Phosphatidylinositol 3-Kinase-Independent Pathway Cancer Res., February 15, 2006; 66(4): 2376 - 2384. [Abstract] [Full Text] [PDF]

				C. A. Granville, R. M. Memmott, J. J. Gills, and P. A. Dennis Handicapping the Race to Develop Inhibitors of the Phosphoinositide 3-Kinase/Akt/Mammalian Target of Rapamycin Pathway Clin. Cancer Res., February 1, 2006; 12(3): 679 - 689. [Abstract] [Full Text] [PDF]

				Y. Luo, A. R. Shoemaker, X. Liu, K. W. Woods, S. A. Thomas, R. de Jong, E. K. Han, T. Li, V. S. Stoll, J. A. Powlas, et al. Potent and selective inhibitors of Akt kinases slow the progress of tumors in vivo Mol. Cancer Ther., June 1, 2005; 4(6): 977 - 986. [Abstract] [Full Text] [PDF]

				A. Ferrand, C. Bertrand, G. Portolan, G. Cui, J. Carlson, L. Pradayrol, D. Fourmy, M. Dufresne, T. C. Wang, and C. Seva Signaling Pathways Associated with Colonic Mucosa Hyperproliferation in Mice Overexpressing Gastrin Precursors Cancer Res., April 1, 2005; 65(7): 2770 - 2777. [Abstract] [Full Text] [PDF]

				K. Yamaguchi, S.-H. Lee, T. E. Eling, and S. J. Baek Identification of Nonsteroidal Anti-inflammatory Drug-activated Gene (NAG-1) as a Novel Downstream Target of Phosphatidylinositol 3-Kinase/AKT/GSK-3{beta} Pathway J. Biol. Chem., November 26, 2004; 279(48): 49617 - 49623. [Abstract] [Full Text] [PDF]

				H. Kato, S. Semba, U. A. Miskad, Y. Seo, M. Kasuga, and H. Yokozaki High Expression of PRL-3 Promotes Cancer Cell Motility and Liver Metastasis in Human Colorectal Cancer: A Predictive Molecular Marker of Metachronous Liver and Lung Metastases Clin. Cancer Res., November 1, 2004; 10(21): 7318 - 7328. [Abstract] [Full Text] [PDF]

				S. Semba, N. Itoh, M. Ito, E. M. Youssef, M. Harada, T. Moriya, W. Kimura, and M. Yamakawa Down-Regulation of PIK3CG, a Catalytic Subunit of Phosphatidylinositol 3-OH Kinase, by CpG Hypermethylation in Human Colorectal Carcinoma Clin. Cancer Res., December 1, 2002; 8(12): 3824 - 3831. [Abstract] [Full Text] [PDF]